A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 5, 2010, Pages 1420-1426

  Murphy, James D ^a   Christman Skieller, Claudia ^a   Kim, Jeff ^a   Dieterich, Sonja ^a   Chang, Daniel T ^a   Koong, Albert C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lyman model; NTCP; Pancreas cancer; SBRT; Toxicity

Indexed keywords

COX REGRESSION; DOSE ESCALATION; DOSE-VOLUME HISTOGRAMS; DOSIMETRIC MODELS; KAPLAN-MEIER; LYMAN MODEL; MODEL OPTIMIZATION; MULTI VARIATE ANALYSIS; NORMAL TISSUE; NORMAL TISSUE COMPLICATION PROBABILITIES; NTCP; PANCREAS CANCER; PANCREATIC ADENOCARCINOMA; PANCREATIC CANCERS; SBRT; STEREOTACTIC BODY RADIOTHERAPY; UNIVARIATE;

DOSIMETERS; DOSIMETRY; FAULT TOLERANT COMPUTER SYSTEMS; MULTIVARIANT ANALYSIS; NATURAL LANGUAGE PROCESSING SYSTEMS; RADIOTHERAPY; REGRESSION ANALYSIS;

TOXICITY;

FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; DOSIMETRY; DUODENUM PERFORATION; DUODENUM ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTOGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT INDICATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, RADIATION; DUODENUM; FEMALE; FIDUCIAL MARKERS; HUMANS; MALE; MIDDLE AGED; ORGANS AT RISK; PANCREATIC NEOPLASMS; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 78549293230     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.09.075     Document Type: Article

References (34)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
2. S.F. Sener, A. Fremgen, and H.R. Menck Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1999 1 7
3. C.G. Moertel, S. Frytak, and R.G. Hahn Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group Cancer 48 1981 1705 1710
4. S.J. Cohen, R. Dobelbower, and S. Lipsitz A randomized Phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282 Int J Radiat Oncol Biol Phys 62 2005 1345 1350
5. P.J. Loehrer, M.E. Powell, and H.R. Cardenes A randomized Phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 J Clin Oncol suppl 2008 26 abstract 4506
6. J.D. Murphy, S. Adusumilli, and K.A. Griffith Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 68 2007 801 808
7. E. Ben-Josef, A.F. Shields, and U. Vaishampayan Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer Int J Radiat Oncol Biol Phys 59 2004 454 459
8. A. Brade, J. Brierley, and A. Oza Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: A Phase I-II study Int J Radiat Oncol Biol Phys 67 2007 1027 1036
9. J.D. Earle, J.F. Foley, and H.S. Wieand Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer Int J Radiat Oncol Biol Phys 28 1994 207 211
10. C.G. Willett, B.G. Czito, and J.C. Bendell Locally advanced pancreatic cancer J Clin Oncol 23 2005 4538 4544
11. A.C. Koong, Q.T. Le, and A. Ho Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 58 2004 1017 1021
12. D. Schellenberg, K.A. Goodman, and F. Lee Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer Int J Radiat Oncol Biol Phys 72 2008 678 686
13. D.T. Chang, D. Schellenberg, and J. Shen Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas Cancer 115 2009 665 672
14. A. Schweikard, H. Shiomi, and J. Adler Respiration tracking in radiosurgery Med Phys 31 2004 2738 2741
15. K.H. Wong, S. Dieterich, and J. Tang Quantitative measurement of CyberKnife robotic arm steering Technol Cancer Res Treat 6 2007 589 594
16. D. Schellenberg, J. Kim, and L. Columbo Phase II trial of single fraction stereotactic body radiotherapy delivered by trilogy linear accelerator for the treatment of locally advanced adenocarcinoma of the pancreas Int J Radiat Oncol Biol Phys 72 2008 S127
17. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0.
18. G.J. Kutcher, and C. Burman Calculation of complication probability factors for non-uniform normal tissue irradiation: The effective volume method Int J Radiat Oncol Biol Phys 16 1989 1623 1630
19. J.T. Lyman Complication probability as assessed from dose-volume histograms Radiat Res Suppl 8 1985 S13 S19
20. B.J.T. Morgan Analysis of quantal response data 1992 Chapman & Hall New York
21. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
22. D.R. Cox Regression models and life tables J Royal Stat Soc Series B 34 1972 187 220
23. M. Lee, J. Kim, and R. Dinniwell Phase I study of individualized stereotactic body radiotherapy of liver metastases J Clin Oncol 27 2009 1585 1591
24. K.E. Rusthoven, B.D. Kavanagh, and H. Cardenes Multi-institutional Phase I/II trial of stereotactic body radiation therapy for liver metastases J Clin Oncol 27 2009 1572 1578
25. M. Hoyer, H. Roed, and A. Hansen Phase II study on stereotactic body radiotherapy of colorectal metastases Acta Oncol 45 2006 823 830
26. R. Tse, M. Hawkins, and G. Lockwood Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma J Clin Oncol 26 2008 657 664
27. M. Hoyer, H. Roed, and L. Sengelov Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma Radiother Oncol 76 2005 48 53
28. C. Park, L. Papiez, and S. Zhang Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy Int J Radiat Oncol Biol Phys 70 2008 847 852
29. H.M. Ceha, G. van Tienhoven, and D.J. Gouma Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma Cancer 89 2000 2222 2229
30. S.M. de Lange, C.J. van Groeningen, and O.W. Meijer Gemcitabine- radiotherapy in patients with locally advanced pancreatic cancer Eur J Cancer 38 2002 1212 1217
31. C.S. Potten A comprehensive study of the radiobiological response of the murine (BDF1) small intestine Int J Radiat Biol 58 1990 925 973
32. F. Paris, Z. Fuks, and A. Kang Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 293 2001 293 297
33. J.S. Cupp, A.C. Koong, and G.A. Fisher Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies Clin Oncol 20 2008 69 75
34. S.E. Tenn, T.D. Solberg, and P.M. Medin Targeting accuracy of an image guided gating system for stereotactic body radiotherapy Phys Med Biol 50 2005 5443 5462